Hide metadata

Cost-utility analysis of ramucirumab after sorafenib for hepatocellular carcinoma patients with alpha-fetoprotein concentration >400ng/ml in the Norwegian healthcare setting - selection of the optimal distribution

dc.contributor.authorKrga, Milica
dc.date.accessioned2020-11-06T23:48:17Z
dc.date.issued2020
dc.identifier.citationKrga, Milica. Cost-utility analysis of ramucirumab after sorafenib for hepatocellular carcinoma patients with alpha-fetoprotein concentration >400ng/ml in the Norwegian healthcare setting - selection of the optimal distribution. Master thesis, University of Oslo, 2020
dc.identifier.urihttp://hdl.handle.net/10852/80919
dc.description.abstracteng
dc.language.isoeng
dc.subject
dc.titleCost-utility analysis of ramucirumab after sorafenib for hepatocellular carcinoma patients with alpha-fetoprotein concentration >400ng/ml in the Norwegian healthcare setting - selection of the optimal distributioneng
dc.typeMaster thesis
dc.date.updated2020-11-07T23:46:49Z
dc.creator.authorKrga, Milica
dc.date.embargoenddate3020-07-31
dc.rights.termsDette dokumentet er ikke elektronisk tilgjengelig etter ønske fra forfatter. Tilgangskode/Access code A
dc.identifier.urnURN:NBN:no-84001
dc.type.documentMasteroppgave
dc.rights.accessrightsclosedaccess
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/80919/1/Master-Thesis_MilicaKrga.pdf


Files in this item

Name:
Master-Thesis_MilicaKrga.pdf
Size:
2.882Mb
Format:
application/
View/Open

Appears in the following Collection

Hide metadata